Roche CEO Sev­erin Schwan isn’t about to tam­per with a win­ning R&D strat­e­gy now, but he’s still look­ing for ways to cut costs

For years now Roche has dom­i­nat­ed the very top cir­cle of Big Phar­ma R&D, in­vest­ing more than $8 bil­lion a year in drug de­vel­op­ment through a glob­al net­work of re­search cen­ters con­cen­trat­ed at Chugai, gRED in South San Fran­cis­co and pRED out of Basel. And as far as CEO Sev­erin Schwan is con­cerned, that’s a win­ning for­mu­la that he has no plans to tam­per with, even as Roche digs in­to its vast R&D ops in search of some greater ef­fi­cien­cies.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.